Journal of Immunotherapy and Precision Oncology: 2023, vol: 6, issue: 4
1)- Daniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, Michael J Morris, Susan F Slovin, Wassim Abida, Erica D Cohn, Raymond E Baser, Howard I Scher, Karen A Autio. Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.Journal of immunotherapy and precision oncology. 2023, 6 (4): 162-169
2)- Hasan Cagri Yildirim, Fatih Kus, Deniz Can Guven, Ece Karaca, Yunus Kaygusuz, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab.Journal of immunotherapy and precision oncology. 2023, 6 (4): 170-176
4)- Andrés F Cardona, Vaneza Ávila, Oscar Arrieta. Treatment for Advanced Non-Small Lung Cancer (NSCLC) with Mutated in Low- and Middle-Income Countries (LMICs).Journal of immunotherapy and precision oncology. 2023, 6 (4): 185-186
5)- Lydia Melissourgou-Syka, Michael A Gillespie, Sean M O'Cathail, Owen J Sansom, Colin W Steele, Campbell S D Roxburgh. A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer.Journal of immunotherapy and precision oncology. 2023, 6 (4): 187-197
6)- Daniel Huff, Shannon Fortin Ensign, Margaret S Ryan, Jeanne Palmer, Javier Munoz. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review.Journal of immunotherapy and precision oncology. 2023, 6 (4): 198-202
7)- . Erratum to "Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature" by Soto et al.Journal of immunotherapy and precision oncology. 2023, 6 (4): 203